ADPT · NASDAQ · STOCK
Adaptive Biotechnologies Corporation
$25.39
52W $11.92 – $26.16
59/100
$4.06B
-62.3
2.09
Is ADPT Bullish or Bearish?
Mixed.
Innellis AI committee rates Adaptive Biotechnologies Corporation (ADPT) Watch with a composite score of 59/100
, based on 6 analysts with 50% agreement.
Last updated August 11, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +1.04 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -18.96 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 50.1% yoy -- genuine top-line momentum. Value Analyst remains cautious — price-to-book of 11.3x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Revenue growing 50.1% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price-to-book of 11.3x prices in significant intangible value — Value
- ROE of only -32.6% -- cheap may mean cheap for a reason — Value
- Weekly RSI at 85 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 20.1% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
59/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 55%
of 192 Healthcare peers
Value Analyst
bearish
30
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− Price-to-book of 11.3x prices in significant intangible value
Growth Analyst
bullish
85
/ 100 · Low confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 50.1% YoY -- genuine top-line momentum
Technical Analyst
bullish
69
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− Weekly RSI at 85 -- overbought on the larger timeframe too
Risk Analyst
bearish
35
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 20.1% signals elevated volatility
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
neutral
58
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
67.3
Neutral
MACD Histogram
0.099
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Bollinger %B
0.96
Inside Bands
Price vs Moving Averages
EMA 9
$24.35
Above
EMA 21
$23.21
Above
EMA 50
$20.98
Above
EMA 200
$16.89
Above
Fundamental Analysis
Valuation
67
Profitability
25
Financial Health
50
Cash Flow
15
Valuation
P/E Ratio
-62.3×
P/B Ratio
28.02×
PEG Ratio
-1.24
Dividend Yield
0.00%
52W High
$26.16
52W Low
$11.92
Quality & Growth
ROE
-2719.4%
ROA
-1160.4%
Gross Margin
7543.6%
Operating Margin
-1215.9%
Revenue Growth YoY
—
Debt / Equity
2.87
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of -62.3 (inexpensive relative to a 15-40x range); Price-to-book of 28.0x; PEG ratio of -1.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -27.2%; Return on assets of -11.6%; Net margin of -20.7%; Gross margin of 75.4%; Current ratio of 4.79 (healthy short-term liquidity); Debt-to-equity of 2.87; Free cash flow per share is negative (-0.15); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full ADPT Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →